With respect to PSMA-targeting, several types of nanoparticles have been outfitted with various types targeting agents (e.g., antibodies, aptamers, urea inhibitors) demonstrating their utility for in vitro and in vivo prostate cancer applications [202,203,204]. This evidence concerns the gene FOLH1 and Familial prostate cancer.